Denufosol

[Brad]

Dear Friend,

We have good news! Today, Inspire Pharmaceuticals announced positive results from the first Phase 3 clinical trial of denufosol, an inhaled drug that targets the basic defect in cystic fibrosis.

CF patients who took the drug showed significant improvement in lung function. Denufosol aims to treat the basic defect by using an alternative chloride transport channel, which allows sodium and chloride to move in and out of the cell, thereby enhancing mucus hydration and clearance.

The Cystic Fibrosis Foundation has been involved from the very beginning, funding basic science research of alternate chloride channels, which led to the development of denufosol. The Foundation has worked closely with Inspire during the drug's development and provided funding for a key Phase 2 clinical trial.

We need your help to complete development of denufosol, so the drug can be brought to market. You can make a difference by participating in the final Phase 3 clinical trial of denufosol. To learn about participating in the final denufosol clinical trial?or other clinical trials?please click here. Or, call (877) 8CF-JOIN.

To learn more about this promising development, please visit the CF Foundation's Web site to read our news story and the announcement issued by Inspire Pharmaceuticals.

Thank you for all you are doing to bring us one step closer to a cure.

Sincerely yours,

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814
(800) FIGHT CF
E-mail: info@cff.org
Web: www.cff.org
Find your local chapter

P.S. To support our efforts, forward this message and learn more about participating in a clinical trial.

 

[Brad]

Dear Friend,

We have good news! Today, Inspire Pharmaceuticals announced positive results from the first Phase 3 clinical trial of denufosol, an inhaled drug that targets the basic defect in cystic fibrosis.

CF patients who took the drug showed significant improvement in lung function. Denufosol aims to treat the basic defect by using an alternative chloride transport channel, which allows sodium and chloride to move in and out of the cell, thereby enhancing mucus hydration and clearance.

The Cystic Fibrosis Foundation has been involved from the very beginning, funding basic science research of alternate chloride channels, which led to the development of denufosol. The Foundation has worked closely with Inspire during the drug's development and provided funding for a key Phase 2 clinical trial.

We need your help to complete development of denufosol, so the drug can be brought to market. You can make a difference by participating in the final Phase 3 clinical trial of denufosol. To learn about participating in the final denufosol clinical trial?or other clinical trials?please click here. Or, call (877) 8CF-JOIN.

To learn more about this promising development, please visit the CF Foundation's Web site to read our news story and the announcement issued by Inspire Pharmaceuticals.

Thank you for all you are doing to bring us one step closer to a cure.

Sincerely yours,

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814
(800) FIGHT CF
E-mail: info@cff.org
Web: www.cff.org
Find your local chapter

P.S. To support our efforts, forward this message and learn more about participating in a clinical trial.

 

[Brad]

Dear Friend,

We have good news! Today, Inspire Pharmaceuticals announced positive results from the first Phase 3 clinical trial of denufosol, an inhaled drug that targets the basic defect in cystic fibrosis.

CF patients who took the drug showed significant improvement in lung function. Denufosol aims to treat the basic defect by using an alternative chloride transport channel, which allows sodium and chloride to move in and out of the cell, thereby enhancing mucus hydration and clearance.

The Cystic Fibrosis Foundation has been involved from the very beginning, funding basic science research of alternate chloride channels, which led to the development of denufosol. The Foundation has worked closely with Inspire during the drug's development and provided funding for a key Phase 2 clinical trial.

We need your help to complete development of denufosol, so the drug can be brought to market. You can make a difference by participating in the final Phase 3 clinical trial of denufosol. To learn about participating in the final denufosol clinical trial?or other clinical trials?please click here. Or, call (877) 8CF-JOIN.

To learn more about this promising development, please visit the CF Foundation's Web site to read our news story and the announcement issued by Inspire Pharmaceuticals.

Thank you for all you are doing to bring us one step closer to a cure.

Sincerely yours,

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814
(800) FIGHT CF
E-mail: info@cff.org
Web: www.cff.org
Find your local chapter

P.S. To support our efforts, forward this message and learn more about participating in a clinical trial.

 

[Brad]

Dear Friend,

We have good news! Today, Inspire Pharmaceuticals announced positive results from the first Phase 3 clinical trial of denufosol, an inhaled drug that targets the basic defect in cystic fibrosis.

CF patients who took the drug showed significant improvement in lung function. Denufosol aims to treat the basic defect by using an alternative chloride transport channel, which allows sodium and chloride to move in and out of the cell, thereby enhancing mucus hydration and clearance.

The Cystic Fibrosis Foundation has been involved from the very beginning, funding basic science research of alternate chloride channels, which led to the development of denufosol. The Foundation has worked closely with Inspire during the drug's development and provided funding for a key Phase 2 clinical trial.

We need your help to complete development of denufosol, so the drug can be brought to market. You can make a difference by participating in the final Phase 3 clinical trial of denufosol. To learn about participating in the final denufosol clinical trial?or other clinical trials?please click here. Or, call (877) 8CF-JOIN.

To learn more about this promising development, please visit the CF Foundation's Web site to read our news story and the announcement issued by Inspire Pharmaceuticals.

Thank you for all you are doing to bring us one step closer to a cure.

Sincerely yours,

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814
(800) FIGHT CF
E-mail: info@cff.org
Web: www.cff.org
Find your local chapter

P.S. To support our efforts, forward this message and learn more about participating in a clinical trial.

 

[Brad]

Dear Friend,
<br />
<br />We have good news! Today, Inspire Pharmaceuticals announced positive results from the first Phase 3 clinical trial of denufosol, an inhaled drug that targets the basic defect in cystic fibrosis.
<br />
<br />CF patients who took the drug showed significant improvement in lung function. Denufosol aims to treat the basic defect by using an alternative chloride transport channel, which allows sodium and chloride to move in and out of the cell, thereby enhancing mucus hydration and clearance.
<br />
<br />The Cystic Fibrosis Foundation has been involved from the very beginning, funding basic science research of alternate chloride channels, which led to the development of denufosol. The Foundation has worked closely with Inspire during the drug's development and provided funding for a key Phase 2 clinical trial.
<br />
<br />We need your help to complete development of denufosol, so the drug can be brought to market. You can make a difference by participating in the final Phase 3 clinical trial of denufosol. To learn about participating in the final denufosol clinical trial?or other clinical trials?please click here. Or, call (877) 8CF-JOIN.
<br />
<br />To learn more about this promising development, please visit the CF Foundation's Web site to read our news story and the announcement issued by Inspire Pharmaceuticals.
<br />
<br />Thank you for all you are doing to bring us one step closer to a cure.
<br />
<br />Sincerely yours,
<br />
<br />Robert J. Beall, Ph.D.
<br />President and CEO
<br />Cystic Fibrosis Foundation
<br />6931 Arlington Road
<br />Bethesda, MD 20814
<br />(800) FIGHT CF
<br />E-mail: info@cff.org
<br />Web: www.cff.org
<br />Find your local chapter
<br />
<br />P.S. To support our efforts, forward this message and learn more about participating in a clinical trial.
<br />
<br />

 

[cfsucks]

how long before it will be on the market if all goes well.

 

[cfsucks]

how long before it will be on the market if all goes well.

 

[cfsucks]

how long before it will be on the market if all goes well.

 

[cfsucks]

how long before it will be on the market if all goes well.

 

[cfsucks]

how long before it will be on the market if all goes well.

 

[Wheezie]

P.S. if your FEV1 is below 75%, you're help is not needed. I Wish they'd tell you that up front instead of sending you on a wild goose, link-clicking, chase for no GD reason. Seriously, how difficult would it be to include one extra sentence in that email, Mr. Beall, that simply said you were only looking for 'healthy' cystics?

 

[Wheezie]

P.S. if your FEV1 is below 75%, you're help is not needed. I Wish they'd tell you that up front instead of sending you on a wild goose, link-clicking, chase for no GD reason. Seriously, how difficult would it be to include one extra sentence in that email, Mr. Beall, that simply said you were only looking for 'healthy' cystics?

 

[Wheezie]

P.S. if your FEV1 is below 75%, you're help is not needed. I Wish they'd tell you that up front instead of sending you on a wild goose, link-clicking, chase for no GD reason. Seriously, how difficult would it be to include one extra sentence in that email, Mr. Beall, that simply said you were only looking for 'healthy' cystics?

 

[Wheezie]

P.S. if your FEV1 is below 75%, you're help is not needed. I Wish they'd tell you that up front instead of sending you on a wild goose, link-clicking, chase for no GD reason. Seriously, how difficult would it be to include one extra sentence in that email, Mr. Beall, that simply said you were only looking for 'healthy' cystics?

 

[Wheezie]

P.S. if your FEV1 is below 75%, you're help is not needed. I Wish they'd tell you that up front instead of sending you on a wild goose, link-clicking, chase for no GD reason. Seriously, how difficult would it be to include one extra sentence in that email, Mr. Beall, that simply said you were only looking for 'healthy' cystics?
<br />
<br />
<br />

 

[NoExcuses]

If you read Inspire's web site, they state the FEV1 requirement explicitly.

And it's not like the more moderate or severe cystics aren't needed, the drug just isn't as effective. to get the drug approved in the quickest time possible, you want to get the best results possible.

This requirement is actually speeding up the approval process which is good for all cFers.

 

[NoExcuses]

If you read Inspire's web site, they state the FEV1 requirement explicitly.

And it's not like the more moderate or severe cystics aren't needed, the drug just isn't as effective. to get the drug approved in the quickest time possible, you want to get the best results possible.

This requirement is actually speeding up the approval process which is good for all cFers.

 

[NoExcuses]

If you read Inspire's web site, they state the FEV1 requirement explicitly.

And it's not like the more moderate or severe cystics aren't needed, the drug just isn't as effective. to get the drug approved in the quickest time possible, you want to get the best results possible.

This requirement is actually speeding up the approval process which is good for all cFers.

 

[NoExcuses]

If you read Inspire's web site, they state the FEV1 requirement explicitly.

And it's not like the more moderate or severe cystics aren't needed, the drug just isn't as effective. to get the drug approved in the quickest time possible, you want to get the best results possible.

This requirement is actually speeding up the approval process which is good for all cFers.

 

[NoExcuses]

If you read Inspire's web site, they state the FEV1 requirement explicitly.
<br />
<br />And it's not like the more moderate or severe cystics aren't needed, the drug just isn't as effective. to get the drug approved in the quickest time possible, you want to get the best results possible.
<br />
<br />This requirement is actually speeding up the approval process which is good for all cFers.